Combined archive search across FBI Vault, SPLC, PHMPT, ACIP, NIH grants, the Federal Writers' Project, and other collections we've ingested.
Brian Frederick Pickering · CHIMERNA THERAPEUTICS INC. · 2024 · $297,608 — SUMMARY: Circular RNAs (circRNAs) are a novel class of RNAs that hold immense potential as therapeutics due to their unique cellular functions. However, the challenges associated with their synthesis and purification have impeded their research and development. Chimerna proposes to develop a platfor…
Xiangfei Han · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $49,225 — ABSTRACT Protein replacement therapy has been a cornerstone in treating genetic diseases (e.g., hemophilia) with loss or reduction of the function of a particular protein, by using recombinant proteins or recombinant engineered proteins. However, most protein therapeutics have short circulation live…
Vitaly V. Ganusov · TEXAS BIOMEDICAL RESEARCH INSTITUTE · 2024 · $634,089 — Research Summary Tuberculosis (TB), a disease caused by the bacteria Mycobacterium tuberculosis (Mtb), remains a major infec- tious disease of humans in the world. After the initial local infection of one site in the lung Mtb somehow dissem- inates in the lung and often spreads beyond the lung. In f…
Guido Ferrari · DUKE UNIVERSITY · 2024 · $5,733,658 — ABSTRACT The ultimate goal of the proposed studies is to contribute to ending the HIV/AIDS epidemic. It has been four decades since the start of the HIV/AIDS epidemic and a protective vaccine or functional cure has been elusive. In 2020, there was an estimated 37.6 million people living with HIV. D…
Xiang-Jun Lu · COLUMBIA UNIV NEW YORK MORNINGSIDE · 2024 · $522,974 — X3DNA-DSSR is a unique resource that excels in structural bioinformatics of nucleic acids. The proposed resource builds upon the features and large user base of 3DNA and DSSR enabled by the grant R01GM096889 on “Continued Development and Maintenance of the 3DNA Suite of Programs” (June 2011 to Augus…
Duane R. Wesemann · BRIGHAM AND WOMEN'S HOSPITAL · 2024 · $686,383 — Project Summary Antibodies specific for pathogenic threats can provide immediate protection from infectious disease but longevity of an antibody responses after vaccination or infection can be highly variable. Responses induced by some live vaccines can persist for a lifetime, whereas protein-based …
Zhongchao Zhao · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2024 · $130,350 — PROJECT SUMMARY/ABSTRACT Ovarian cancer is the most lethal gynecologic malignancy for women; standard of care surgery and chemotherapy treatment can provide a short period of remission but cannot eradicate the disease and prevent recurrence. Cancer immunotherapy has shown great potential in treating…
Julia Meghan Davis-Porada · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2024 · $50,974 — PROJECT SUMMARY Vaccines save lives, and the rapid development of novel vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was a triumph for the medical community. While the rapid deployment of these vaccines has undoubtedly attenuated the severe morbidity and mortality in…
Marian L Kohut · IOWA STATE UNIVERSITY · 2024 · $191,250 — PROJECT SUMMARY / ABSTRACT Vaccination is an effective public health measure, yet host factors including advanced age, sex, obesity, physical or mental health status may influence vaccine efficacy. Adjuvants improve immunogenicity to vaccination but often result in greater side effects. As an alter…
Steven M Lipkin · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $115,661 — Admin Core: Project Summary/Abstract A significant overall goal of CAP-IT is to identify and validate immunologically targeted agents for precision prevention of individuals with increased cancer risk. The CAP-IT Center for RNA Immunoprevention (CRI) Administrative Core (AC) mission is to ensure tha…
Steven M Lipkin · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $433,293 — PROJECT SUMMARY Computerized chest tomography (CT) lung cancer screening programs have increased the detection of premalignant non-solid (NS) nodules that harbor preinvasive or minimally invasive adenocarcinoma. Given that NS nodules can progress to invasive adenocarcinoma (solid nodules), interce…
Benjamin L Miller · UNIVERSITY OF ROCHESTER · 2024 · $369,041 — Abstract The field of Osteoimmunology was established in 2005 to understand how bone influences immune and hematopoietic cells, as well as how hematopoietic and immune cells influence bone, in clinical conditions like osteomyelitis. However, several critical research tools and rigorously validated p…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $511,558 — The Administrative Core A, led by Dr. Richard Wyatt, will administer support for Projects 1 and 2 and Cores B and C, under the umbrella of this new HIVRAD proposal. This Core will coordinate an administrative partnership plan to maintain good communications within the HIVRAD working group and rele…
DAVID MCCORMICK · IIT RESEARCH INSTITUTE · 2024 · $1,020,618 — PRECLINICAL DEVELOPMENT OF AN RNA VACCINE FOR IMMUNOPREVENTION OF PROSTATE CANCER…
Michael C. Milone · UNIVERSITY OF PENNSYLVANIA · 2024 · $565,591 — PROJECT SUMMARY / ABSTRACT (PROJECT 3) Multiple myeloma (MM) is a hematologic malignancy of bone marrow plasma cells. Even though MM is almost universally fatal, modern therapy has markedly improved survival. Among the most promising new MM therapies are CAR T cells targeting B cell maturation antig…
FRANCOIS VILLINGER · UNIVERSITY OF LOUISIANA AT LAFAYETTE · 2024 · $317,451 — The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prev…
MARGIE L. CLAPPER · RESEARCH INST OF FOX CHASE CAN CTR · 2024 · $515,612 — Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide. In the Unites States, an estimated 151,300 Americans will be diagnosed with CRC and over 52,580 are expected to die from the disease in 2022 alone (https://seer.cancer.gov/statfacts/html/colorect.html). While…
Jesse Hong-Sae Erasmus · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2024 · $2,091,310 — Abstract RNA vaccines have dramatically altered the landscape of vaccine development, affording an unparalleled ability to rapidly counteract emerging infectious diseases, as evidenced by the swift generation of effective RNA vaccines in response to the COVID-19 pandemic. However, despite these majo…
Karen S. Anderson · YALE UNIVERSITY · 2024 · $432,279 — SUMMARY Human papillomavirus (HPV)-associated neck squamous cell carcinoma (HNSCC) represents an increasing proportion of HNSCC. The incidence of HPV+ HNSCC has dramatically increased over the last 2 decades and in 2012 surpassed uterine cervical cancer as the most common HPV-related malignancy in t…
Neil King · UNIVERSITY OF WASHINGTON · 2024 · $5,122,197 — PROJECT SUMMARY – PROJECT 3: ANTIGEN DESIGN Project 3 focuses on developing generalizable approaches to the modeling, design, and evaluation of native-like antigens for arenaviruses, phenuiviruses, and paramyxoviruses. Powerful machine-learning (ML) methods enable stabilization of antigens in desire…